Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 9/20 | 0.38 |
| ▸ | MMP3 | P08254 | 6/20 | 0.38 |
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499695 | 0.95 | CTSS (0.35) | LTA4HMETAP2CTSSCTSKMMP2 | |
| SCHEMBL13500295 | 0.87 | MMP1 (0.38) | LTA4HMETAP2CTSSCTSKMMP2 | |
| SCHEMBL13461499 | 0.84 | METAP2 (0.36) | METAP2CTSSCTSKMMP2BMP1 | |
| SCHEMBL13435033 | 0.84 | CPB2 (0.37) | METAP2CTSSCTSKMMP2MMP3 | |
| SCHEMBL13499691 | 0.81 | LTA4H (0.49) | LTA4HMETAP2CTSSCTSKCTSL | |
| SCHEMBL13499665 | 0.80 | LTA4H (0.48) | LTA4HMETAP2CTSSCTSKCTSL | |
| SCHEMBL13499687 | 0.80 | METAP2 (0.41) | LTA4HMETAP2CTSSCTSKMMP2 | |
| SCHEMBL13499681 | 0.80 | LTA4H (0.48) | LTA4HMETAP2CTSSCTSKMMP2 | |
| SCHEMBL13499662 | 0.80 | LTA4H (0.48) | LTA4HMETAP2CTSSCTSKMMP2 | |
| SCHEMBL13500154 | 0.80 | MMP1 (0.32) | CTSSCTSKMMP2MMP3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | LTA4H 2299/4885METAP2 1006/4885CTSS 121/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | LTA4H 2299/4885METAP2 1006/4885CTSS 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.